Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Placebo; Drug: Glimepiride
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Spinal Cord Injury
Interventions: Device: ReJoyce Workstation; Other: Standard Care
Sponsors: University of Melbourne; Victorian Neurotrauma Initiative; Life Time Care and Support Authority (NSW); University of Western Australia
Recruiting - verified March 2010
Conditions: Anterior Cruciate Ligament Injury; Osteoarthritis
Interventions: Biological: MSB-CAR001 Combined With Hyaluronan; Drug: Hyaluronan
Sponsor: Mesoblast, Ltd.
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992; Drug: Investigator´s choice of chemotherapy
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: linagliptin; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: PT003 MDI; Drug: PT005 MDI; Drug: Placebo MDI; Drug: Tiotropium bromide 18 μg (Spiriva Handihaler®); Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®); Drug: PT001 MDI
Sponsor: Pearl Therapeutics, Inc.
Recruiting - verified March 2010
Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsor: Hamilton Health Sciences
Not yet recruiting - verified March 2010
Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
Intervention: Drug: olaparib
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin Glargine; Drug: LY2189265
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsor: Celgene Corporation
Not yet recruiting - verified February 2010